INFECTIOUS DISEASE RESEARCH INSTITUTE
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : b************a@a**i.o*g
Mission Statement
As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. IDRI combines passion for improving human health with the understanding that it is not just what our scientists know about disease, but what we do to change its course that will have the greatest impact. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
About This Cause
Founded in Seattle in 1993, the Infectious Disease Research Institute (IDRI) is a nonprofit biotechnology organization with the mission of applying innovative science to develop diagnostics, drugs and vaccines to eliminate infectious diseases of global importance. IDRI takes a unique approach, combining the research qualities of an academic organization with the capabilities of a biotech company. IDRI’s internal product development programs focus on leprosy, tuberculosis and leishmaniasis, and we partner with nearly 100 organizations around the world to find new solutions for these and other devastating infectious diseases, including malaria, HIV/AIDS and pandemic flu. We are also tackling emerging diseases including chikungunya and West Nile virus. With extensive experience in basic and applied research within the areas of molecular biology, biochemistry, immunology and process sciences, IDRI has unique expertise in the areas of inventing and producing vaccine technologies, which have broad applicability and are key to the development of effective, low cost vaccines. After more than 20 years, IDRI has concrete progress to report: diagnostics on the market, vaccines in clinical trials, and drugs being discovered and in development. • More than 13 million diagnostics using IDRI technology are on the market for leishmaniasis, Chagas disease & leprosy. • IDRI has vaccines in clinical trials, including a promising tuberculosis candidate that was successfully tested in the U.S. before moving into clinical trials in South Africa, which are currently under way. We have conducted 10 trials for leishmaniasis vaccines and 3 trials for TB vaccines. • IDRI scientists have screened over 500,000 chemical compounds, feeding a pipeline of new drugs for tuberculosis.